Strontium-89 Chloride Injection for Relief of Pain in Bone Metastases

Overview:

Injections of Strontium-89 chloride are useful for pain relief from bone metastases, especially from prostate carcinoma. Studies have shown significantly improved results, with some patients reporting complete relief of pain. The treatment is typically without significant side effects and is very well tolerated. The relief of pain typically occurs within ten to 20 days and lasts up to six months. Its dosage can provide absorbed high doses with therapeutic effects; hence, it should be administered during pain treatment of bone metastases.

Drug Group:

Strontium-89 chloride injection is a radioisotope drug. The medicament reaches the metastatic bone lesions, particularly within prostate and breast cancer cases, so the ionizing radiation spots cancer, thereby decreasing the discomfort in bones.

Dosages:

Administration: The recommended dose of Strontium-89 chloride injection for intravenous injection is 148 MBq (megabecquerel) or four mCi (millicurie). The injection should be given slowly for one to two minutes. Recommended alternative dosages are 1.5-2.2 MBq/kg (megabecquerel per kilogram) or 40-60 µCi/kg (microcurie per kilogram) body weight. Generally, repeated Strontium-89 chloride injections at intervals of less than ninety days are not recommended; instead, they should be based on each patient's response to therapy, current symptoms, and hematologic status. A good radioactivity calibration system should be used to measure a patient's dose before administering it.

For Patients:

How Does Strontium-89 Chloride Injection Alleviate Pain From Bone Metastases?

Cancer cells from a primary tumor can spread to bones, forming secondary tumors called bone metastases, which cause painful bone lesions. These metastases are common in cancers like breast and prostate, often requiring a multidisciplinary approach for pain relief and quality of life management. Strontium-89 chloride injections are a treatment specifically for pain caused by bone metastases. This drug works by delivering radiation directly to the cancerous areas in the bone, targeting sites of new bone growth (where metastases form). The radiation reduces pain by 50 to 80 percent, with relief typically starting within 10 to 20 days and lasting up to six months. This makes Strontium-89 a valuable option for managing bone pain in cancer patients.

What Must the Patient Inform the Doctor Before Taking Strontium-89 Chloride Injection?

Patients suffering from bone marrow disease, blood diseases, kidney disease, or allergy to Strontium-89 chloride must notify their physician before receiving this medication as an injection. All the medications they are on must be listed, including all vitamins and Aspirin. Pregnant or nursing women should also inform their physician because Strontium-89 chloride may interfere with menstrual cycles and sperm production. Since there is a risk of possible conception and, hence, to the fetus, the given treatment using effective birth control is extremely important.

What Are the Side Effects of Using Strontium-89 Chloride Injection to Relieve Pain in Bone Metastases?

• Flushing.

• Diarrhea.

• Fatigue.

• Increased pain.

• Decreased blood cells.

For Doctors:

Description:

Strontium-89 chloride is a sterile, non-pyrogenic, aqueous solution in concentration for intravenous injection. The solution does not contain a preservative. Every milliliter holds the following content: strontium chloride 10.9-22.6mg (milligrams). Injection Water; 1 mL(milliliters). For calibration, specific activity is 2.96 to 6.17 MBq/mg(mega becquerel per milligram), or 80 to167 µCi/mg (microcurie per milligram). At the same time, the radioactive concentration is 37 MBq/mL (mega becquerel per milliliter) or 1 mCi/mL (microcurie per milliliter), and the pH solution is between 4 and 7.5.

Dosage and Administration:

The recommended intravenous injection dose of Strontium-89 chloride is 148 MBq or four mCi administered slowly over one to two minutes. Alternatively, 1.5 to 2.2 MBq/kg, 40 to 60 µCi/kg body weight. Repeated Strontium-89 chloride injections at intervals of less than ninety days are not advisable; however, this may depend on each patient's response to therapy, his current condition, and his hematologic state. A good system for calibrating radioactivity would measure the dose as soon as possible before giving it to the patient.

Indications:

Patients with painful skeletal metastases have received a Strontium-89 chloride injection, which has reduced their bone pain. However, bone metastasis should be confirmed before initiating treatment.

Contraindications:

Injections of Strontium-89 chloride are contraindicated for anyone with bone marrow disease, a blood disorder, a kidney problem, or an allergy to Strontium-89 chloride. It can also affect a female's menstrual period and a male's production of sperm. Pregnant or breastfeeding women should consult their physician for their medical professional to advise them if treatment will endanger their baby before any new medication is prescribed. It is also not advisable for one to plan pregnancies during or immediately after chemotherapy. During treatment, adequate use of contraceptives must be observed to avoid pregnancy.

Warnings and Precautions:

• Allergies: Those allergic to Strontium 89 chloride must not use this medicine.

• Bone Marrow Disease: Strontium 89 chloride must not be given to one with bone marrow.

• Blood Diseases: This medicine must not be administered to a patient with a blood-related disorder

• Kidney Diseases: People with kidney diseases must not be given the drug.

• Menstrual Cycle and Sperm Production: In male patients, it affects sperm production and interferes with regular menstrual cycles in females.

• Pregnancy and Breastfeeding: A female patient must inform her doctor if she is pregnant or breastfeeding since the drug can cause injury to the fetus.

• Birth Control: One should use effective birth control methods during treatment to avoid getting pregnant.

What Are the Adverse Reactions of Strontium-89 Chloride Injection?

• Unusual bruising or bleeding.

• No decrease in pain even after seven days of use.

• Fever and chills.

• Leukopenia.

• Neutropenia.

• Thrombocytopenia.

What Are the Pharmacological Aspects of Strontium-89 Chloride Injection?

1. Mechanism of Action: Injections of Strontium-89 chloride reduce bone pain by delivering radiation to cancer areas. It is a pure radioisotope concentrated in regions with strong bone activity and emits beta particles. Studies report that 80 percent of patients will experience pain relief. Also, 10 to 40 percent have no discomfort at all. Pain relief usually lasts for three to four months. The mechanism of pain relief is related to the absorbed dose in the tumor and bone.

2. Pharmacodynamics: Strontium-89 chloride injection is a site-specific treatment of bone metastases. The therapy is mainly targeted towards the sites of intense bone metabolism. According to various studies, up to 80 percent of patients may have an alleviation in pain, and ten to 40 percent do not experience discomfort. Pain relief usually commences after ten to 20 days but may persist for up to six months. The dose absorbed in the tumor and bone correlates with the pain relief mechanism. It is associated with short-term myelosuppression, one of its side effects. Strontium-89 is considered safe, efficient, and well-tolerated for refractory bone pain.

3. Pharmacokinetics: Strontium-89 chloride concentrates near malignant metastases and is preferentially absorbed at sites with significant bone activity. In time, the therapeutic index improves, favoring tumors that receive effective doses of radiation while exposing as little healthy tissue as possible to these same dosages. Research shows that 80 percent of patients with prostatic metastases can relieve bone pain with a single dose of 150 MBq, but higher doses do not give a higher response rate. Pain relief usually begins after 10 to 20 days of use and lasts up to 6 months. It offers the advantage of having low hematologic toxicity, safe and efficient palliative treatment of refractory bone pain.

Drug Interactions:

• 5-HTP (5-hydroxytryptophan).

• Naproxen.

• Alpha-lipoic acid.

• Aspirin.

• Calcium/vitamin D.

• Calcium carbonate.

• Calcium, Magnesium, and Zinc.

• Celecoxib.

• Ubiquinone.

• Cholecalciferol.

• Dehydroepiandrosterone.

• Apixaban.

• Evening primrose.

• Omega-3 polyunsaturated fatty acids.

• Ibrutinib.

• Ferrous sulfate.

• Polyethylene glycol 3350.

• Acetaminophen.

• Clopidogrel.

• Bifidobacterium infantis / lactobacillus acidophilus.

• Levothyroxine.

• Cyanocobalamin.

• Riboflavin.

• Pyridoxine.

• Ascorbic acid.

• Cholecalciferol.

• Phytonadione.

• Menaquinone.

Use in Specific Populations:

• Pregnancy: Scientific research has indicated that strontium isotopes pass through the placental barrier, accumulate in calcified tissues, and consequently affect the baby's development. Therefore, pregnant women must avoid taking Strontium-89 chloride because it may interfere with the development of the fetus. Just like any other medication, pregnant women should consult a doctor before administering Strontium-89 chloride, as well as any other drug, to prevent harming themselves and their babies.

• Lactation: Studies on radioactive isotopes indicate that Strontium may accumulate in calcified tissues and the embryo and pass to offspring through the placental mechanism or the mammary glands.

Clinical Studies:

It is known that most patients with breast and prostate cancer use Strontium-89 chloride to alleviate their bone pain, but less is known about its efficacy in other patients. This review evaluated 54 patients with painful bone metastases, 26 from prostate or breast cancer, and 28 from other types of cancer: lung and colorectal. Findings showed an associated pain relief in 71.2 percent, with complete relief in 34.6 percent. In general, there was no discernible difference in response between breast or prostate cancer patients and those with other types of malignancies. However, some patients experienced transient elevations in pain as well as severe anemia. Based on this study, it was concluded that Sr-89 chloride does seem to be a potentially useful treatment modality for painful bone metastases, not just for prostate or breast cancer but for other cancers as well.